NovaBridge Biosciences
NBP · XNASCIK 1778016fmd_08RS36FGZCZ24J41DBRSTF5HXCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Dec 31, 2025, 18 periods
| Line item | FY2010 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 12 | 54 | 30 | 1,543 | 88 | (222) | 28 |
| Cost of revenue | – | – | – | 0 | 0 | 46 | 27 | – |
| Gross profit | – | – | – | 30 | 1,543 | 42 | (249) | – |
| Research and development | 44 | 267 | 426 | 840 | 985 | 1,213 | 905 | 811 |
| Interest expense | – | 6 | 12 | 3 | 1 | 0 | 0 | 1 |
| Interest and investment income | – | 1 | 5 | 31 | 24 | 21 | 27 | 52 |
| Other non-operating income (expense) | – | 2 | (17) | (20) | 413 | 83 | (127) | (38) |
| Income before taxes | – | (298) | (401) | (1,452) | 483 | (2,335) | (2,507) | (1,466) |
| Income tax expense | – | – | 2 | 0 | 12 | (3) | 1 | – |
| Net income from continuing operations | – | (281) | (439) | (1,465) | 156 | (2,071) | (1,969) | (1,399) |
| Net income | – | (298) | (403) | (1,452) | 471 | (2,332) | (2,507) | (1,466) |
| Net income to common shareholders | – | (298) | (403) | (1,485) | 471 | (2,332) | (2,507) | (1,466) |